NASDAQ:NK - Nantkwest Stock Price, Forecast & News

Nantkwest trades on the NASDAQ under the ticker symbol "NK."

Nantkwest Inc (NASDAQ:NK) released its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.02. The biotechnology company earned $0.01 million during the quarter. Nantkwest had a negative return on equity of 44.91% and a negative net margin of 164,604.89%. View Nantkwest's Earnings History.

Nantkwest is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Nantkwest.

1 brokers have issued 12-month price targets for Nantkwest's stock. Their forecasts range from $1.00 to $1.00. On average, they expect Nantkwest's share price to reach $1.00 in the next twelve months. This suggests that the stock has a possible downside of 85.2%. View Analyst Price Targets for Nantkwest.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nantkwest in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell." View Analyst Ratings for Nantkwest.

Headlines about NK stock have trended extremely negative on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Nantkwest earned a news sentiment score of -5.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Nantkwest.

Nantkwest saw a increase in short interest in December. As of December 31st, there was short interest totalling 2,830,000 shares, an increase of 34.1% from the December 15th total of 2,110,000 shares. Based on an average daily volume of 640,400 shares, the short-interest ratio is currently 4.4 days. Currently, 10.2% of the company's shares are short sold. View Nantkwest's Current Options Chain.

Some companies that are related to Nantkwest include Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Regenxbio (RGNX), Alector (ALEC), Cortexyme (CRTX), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX), Coherus Biosciences (CHRS), Orchard Therapeutics (ORTX), DBV TECHNOLOGIE/S (DBVT), NanoString Technologies (NSTG), Mesoblast (MESO), Aerie Pharmaceuticals (AERI), Krystal Biotech (KRYS) and BAVARIAN NORDIC/S (BVNRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Nantkwest investors own include Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Novavax (NVAX), Vodafone Group (VOD), NovaBay Pharmaceuticals (NBY), Fate Therapeutics (FATE), Immunomedics (IMMU), Opko Health (OPK) and Bausch Health Companies (BHC).

(NK) raised $150 million in an initial public offering on Tuesday, July 28th 2015. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager.

Nantkwest's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Alpine Global Management LLC (0.01%). Company insiders that own Nantkwest stock include John C Thomas and Steve Gorlin. View Institutional Ownership Trends for Nantkwest.

NK stock was acquired by a variety of institutional investors in the last quarter, including Alpine Global Management LLC. View Insider Buying and Selling for Nantkwest.

Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NK stock can currently be purchased for approximately $6.77.

Nantkwest has a market capitalization of $665.96 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-96,230,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis. Nantkwest employs 161 workers across the globe.View Additional Information About Nantkwest.

The official website for Nantkwest is http://www.nantkwest.com/.

Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]